RT Book, Section
A1 Sibbald, Debra
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1161500512
T1 Acne Vulgaris
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1161500512
RD 2024/04/19
AB Content  UpdateFeb.  19,  2019Sarecycline  (Seysara)  Approved  for  Treatment  of  Acne  Vulgaris:  In  October  2018,  the  FDA  approved  sarecycline  (Seysara),  a  once-daily  oral  tablet  for  treatment  of  inflammatory  lesions  of  non-nodular  moderate  to  severe  acne  vulgaris  in  persons  aged  9  years  and  older.  Sarecycline  is  a  tetracycline  derivative  with  a  narrower  spectrum  of  activity  than  other  tetracyclines,  which  may  result  in  lower  rates  of  bacterial  resistance.  Safety  and  efficacy  of  sarecycline  were  shown  to  be  superior  to  placebo  in  two  identical  phase  3  clinical  trials  lasting  12  weeks.  Adverse  event  rates  were  similar  in  nature  to  other  tetracyclines  and  occurred  at  low  rates.  The  high  cost  of  the  proprietary  product  may  present  a  barrier  to  its  adoption  by  health  system  formularies  and  widespread  use  by  clinicians.  Further  research  into  the  potential  for  reduced  antimicrobial  resistance  is  warranted.